Published in Arthritis Rheum on September 01, 2007
Trial on the Effect of Adalimumab on Vascular Inflammation in Patients With Psoriasis | NCT01722214
IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial. Ann Rheum Dis (2008) 6.97
The immune system in atherosclerosis. Nat Immunol (2011) 6.51
A comparison of patient characteristics and outcomes in selected European and U.S. rheumatoid arthritis registries. Semin Arthritis Rheum (2010) 2.88
Dyslipidemia and changes in lipid profiles associated with rheumatoid arthritis and initiation of anti-tumor necrosis factor therapy. Arthritis Care Res (Hoboken) (2012) 2.72
Cardiovascular disease in patients with rheumatoid arthritis: results from the QUEST-RA study. Arthritis Res Ther (2008) 2.15
Explaining the cardiovascular risk associated with rheumatoid arthritis: traditional risk factors versus markers of rheumatoid arthritis severity. Ann Rheum Dis (2010) 1.76
No evidence of association between anti-tumor necrosis factor treatment and mortality in patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register. Arthritis Rheum (2010) 1.73
Low frequency of primary lipid screening among medicare patients with rheumatoid arthritis. Arthritis Rheum (2011) 1.71
Role for TNF in atherosclerosis? Lessons from autoimmune disease. Nat Rev Cardiol (2009) 1.68
Integrated safety in tocilizumab clinical trials. Arthritis Res Ther (2011) 1.55
Long-term safety of rituximab in rheumatoid arthritis: 9.5-year follow-up of the global clinical trial programme with a focus on adverse events of interest in RA patients. Ann Rheum Dis (2012) 1.54
Inflammatory cytokines and risk of coronary heart disease: new prospective study and updated meta-analysis. Eur Heart J (2013) 1.53
Influence of anti-tumor necrosis factor therapy on cancer incidence in patients with rheumatoid arthritis who have had a prior malignancy: results from the British Society for Rheumatology Biologics Register. Arthritis Care Res (Hoboken) (2010) 1.44
Cardiovascular risk in rheumatoid arthritis: recent advances in the understanding of the pivotal role of inflammation, risk predictors and the impact of treatment. Rheumatology (Oxford) (2014) 1.34
Effects of the anti-interleukin-6 receptor antibody, tocilizumab, on serum lipid levels in patients with rheumatoid arthritis. Rheumatol Int (2009) 1.27
Changes in lipid levels with inflammation and therapy in RA: a maturing paradigm. Nat Rev Rheumatol (2013) 1.20
The inextricable link between atherosclerosis and prototypical inflammatory diseases rheumatoid arthritis and systemic lupus erythematosus. Arthritis Res Ther (2009) 1.15
Sustained changes in lipid profile and macrophage migration inhibitory factor levels after anti-tumour necrosis factor therapy in rheumatoid arthritis. Ann Rheum Dis (2008) 1.12
Levels of C-reactive protein associated with high and very high cardiovascular risk are prevalent in patients with rheumatoid arthritis. PLoS One (2009) 1.09
Disease activity in rheumatoid arthritis and the risk of cardiovascular events. Arthritis Rheumatol (2015) 1.06
Cardiovascular disease in patients with chronic inflammation: mechanisms underlying premature cardiovascular events in rheumatologic conditions. Eur Heart J (2014) 1.04
Vascular effects of biologic agents in RA and spondyloarthropathies. Nat Rev Rheumatol (2009) 1.04
Cardiovascular risk in rheumatoid arthritis: comparing TNF-α blockade with nonbiologic DMARDs. Am J Med (2013) 1.01
Anti-tumor necrosis factor therapy improves insulin resistance, beta cell function and insulin signaling in active rheumatoid arthritis patients with high insulin resistance. Arthritis Res Ther (2012) 0.99
Atherogenic index and high-density lipoprotein cholesterol as cardiovascular risk determinants in rheumatoid arthritis: the impact of therapy with biologicals. Mediators Inflamm (2012) 0.99
Infliximab improves vascular stiffness in patients with rheumatoid arthritis. Ann Rheum Dis (2008) 0.96
Interleukin 17 as a novel predictor of vascular function in rheumatoid arthritis. Ann Rheum Dis (2011) 0.95
The impact of traditional cardiovascular risk factors on cardiovascular outcomes in patients with rheumatoid arthritis: a systematic review and meta-analysis. PLoS One (2015) 0.95
The association between reduction in inflammation and changes in lipoprotein levels and HDL cholesterol efflux capacity in rheumatoid arthritis. J Am Heart Assoc (2015) 0.94
Cardiovascular safety of biologic therapies for the treatment of RA. Nat Rev Rheumatol (2011) 0.92
Anti-TNF-alpha-adalimumab therapy is associated with persistent improvement of endothelial function without progression of carotid intima-media wall thickness in patients with rheumatoid arthritis refractory to conventional therapy. Mediators Inflamm (2012) 0.91
IL-17 induces inflammation-associated gene products in blood monocytes, and treatment with ixekizumab reduces their expression in psoriasis patient blood. J Invest Dermatol (2014) 0.90
Lack of replication of genetic predictors for the rheumatoid arthritis response to anti-TNF treatments: a prospective case-only study. Arthritis Res Ther (2010) 0.89
[Cardiovascular comorbidity and its risk factors in rheumatoid arthritis]. Z Rheumatol (2011) 0.89
Infliximab, a TNF-α inhibitor, reduces 24-h ambulatory blood pressure in rheumatoid arthritis patients. J Hum Hypertens (2013) 0.87
The risk of acute coronary syndrome in rheumatoid arthritis in relation to tumour necrosis factor inhibitors and the risk in the general population: a national cohort study. Arthritis Res Ther (2014) 0.84
What is the future of targeted therapy in rheumatology: biologics or small molecules? BMC Med (2014) 0.83
Relationship between tumor necrosis factor-α inhibitors and cardiovascular disease in psoriasis: a review. Perm J (2014) 0.83
Unresolved questions in rheumatology: motion for debate: the data support evidence-based management recommendations for cardiovascular disease in rheumatoid arthritis. Arthritis Rheum (2013) 0.83
Methotrexate, Cyclosporine A, and Biologics Protect against Atherosclerosis in Rheumatoid Arthritis. J Immunol Res (2015) 0.82
Cardiovascular involvement in autoimmune diseases. Biomed Res Int (2014) 0.82
Impact of disease activity and treatment of comorbidities on the risk of myocardial infarction in rheumatoid arthritis. Arthritis Res Ther (2016) 0.81
Interpreting studies of cardiovascular mortality in rheumatoid arthritis: the importance of timing. Arthritis Rheum (2008) 0.81
Cardiovascular disease and rheumatoid arthritis: an update. Curr Rheumatol Rep (2012) 0.81
Low-dose prednisolone treatment of early rheumatoid arthritis and late cardiovascular outcome and survival: 10-year follow-up of a 2-year randomised trial. BMJ Open (2014) 0.81
Endothelial progenitor cells in arthritis-associated vasculogenesis and atherosclerosis. Joint Bone Spine (2009) 0.81
Multimorbidity in rheumatic conditions. Wien Klin Wochenschr (2016) 0.81
Hydroxychloroquine Use Is Associated With Decreased Incident Cardiovascular Events in Rheumatoid Arthritis Patients. J Am Heart Assoc (2016) 0.80
Biologics, cardiovascular effects and cancer. BMC Med (2014) 0.80
Vascular calcifications on hand radiographs in rheumatoid arthritis and associations with autoantibodies, cardiovascular risk factors and mortality. Rheumatology (Oxford) (2015) 0.80
Long-term frequent use of non-steroidal anti-inflammatory drugs might protect patients with ankylosing spondylitis from cardiovascular diseases: a nationwide case-control study. PLoS One (2015) 0.80
Autoimmune heart disease: role of sex hormones and autoantibodies in disease pathogenesis. Expert Rev Clin Immunol (2012) 0.80
Targeting Low Disease Activity in Elderly-Onset Rheumatoid Arthritis: Current and Future Roles of Biological Disease-Modifying Antirheumatic Drugs. Drugs Aging (2016) 0.79
The practical value of biologics registries in Africa and Middle East: challenges and opportunities. Clin Rheumatol (2012) 0.79
Risk factors for coronary heart disease in connective tissue diseases. Ther Adv Musculoskelet Dis (2010) 0.79
Plasma IL-5 concentration and subclinical carotid atherosclerosis. Atherosclerosis (2014) 0.79
Decreased heart rate variability in patients with psoriatic arthritis. Clin Rheumatol (2012) 0.78
Factors predicting pain and early discontinuation of tumour necrosis factor-α-inhibitors in people with rheumatoid arthritis: results from the British society for rheumatology biologics register. BMC Musculoskelet Disord (2016) 0.77
[Safety of antirheumatic drug treatment in the elderly]. Z Rheumatol (2014) 0.77
Prevalence of dyslipidemia in Japanese patients with rheumatoid arthritis and effects of atorvastatin treatment. Clin Rheumatol (2015) 0.77
Update of the management of chronic psoriasis: new approaches and emerging treatment options. Clin Cosmet Investig Dermatol (2010) 0.76
Metabolic syndrome and chronic arthritis: effects of anti-TNF-α therapy. Clin Exp Med (2014) 0.76
Update on the use of etanercept across a spectrum of rheumatoid disorders. Biologics (2008) 0.76
The JUPITER study: statins for the primary prevention of cardiovascular events in patients with inflammatory rheumatic diseases? F1000 Med Rep (2009) 0.76
Relationship between exposure to tumour necrosis factor inhibitor therapy and incidence and severity of myocardial infarction in patients with rheumatoid arthritis. Ann Rheum Dis (2017) 0.75
Accelerated atherosclerosis in patients with chronic inflammatory rheumatologic conditions. Int J Clin Rheumtol (2015) 0.75
Rituximab for Rheumatoid Arthritis. Rheumatol Ther (2015) 0.75
Comorbidities in Patients with Psoriatic Arthritis. Rambam Maimonides Med J (2017) 0.75
The effect of etanercept on traditional metabolic risk factors for cardiovascular disease in patients with rheumatoid arthritis. Clin Rheumatol (2016) 0.75
The role of adalimumab in rheumatic and autoimmune disorders: comparison with other biologic agents. Open Access Rheumatol (2012) 0.75
Expansions of Cytotoxic CD4(+)CD28(-) T Cells Drive Excess Cardiovascular Mortality in Rheumatoid Arthritis and Other Chronic Inflammatory Conditions and Are Triggered by CMV Infection. Front Immunol (2017) 0.75
Apoptosis in ischemic heart disease. J Transl Med (2017) 0.75
The clinical status and economic savings associated with remission among patients with rheumatoid arthritis: leveraging linked registry and claims data for synergistic insights. Pharmacoepidemiol Drug Saf (2016) 0.75
Acute myocardial infarction complicating active ulcerative colitis: a case report. Case Rep Cardiol (2011) 0.75
What is the impact of biologic therapies on common co-morbidities in patients with rheumatoid arthritis? Arthritis Res Ther (2016) 0.75
Effects of probiotic supplementation on lipid profile of women with rheumatoid arthritis: A randomized placebo-controlled clinical trial. Health Promot Perspect (2017) 0.75
Effects of anti-TNF-α treatment on lipid profile in rheumatic diseases: an analytical cohort study. Arthritis Res Ther (2016) 0.75
An alternative, autonomic rationale for decreased risk of myocardial infarction in patients with rheumatoid arthritis responsive to anti-tumor necrosis factor therapy: comment on the article by Dixon et al. Arthritis Rheum (2008) 0.75
[Biologics and cardiovascular risk]. Z Rheumatol (2010) 0.75
The effect of anti-rheumatic medications for coronary artery diseases risk in patients with rheumatoid arthritis might be changed over time: A nationwide population-based cohort study. PLoS One (2017) 0.75
Genetic and Epigenetic Profiling Reveals EZH2-mediated Down Regulation of OCT-4 Involves NR2F2 during Cardiac Differentiation of Human Embryonic Stem Cells. Sci Rep (2017) 0.75
Sulfasalazine and its metabolites inhibit platelet function in patients with inflammatory arthritis. Clin Rheumatol (2014) 0.75
[Therapy of dyslipidemia in rheumatic diseases]. Z Rheumatol (2010) 0.75
[Risk of atherosclerosis mediated by inflammation in rheumatoid arthritis]. Z Rheumatol (2012) 0.75
Interleukin 6 Inhibition and Coronary Artery Disease in a High-Risk Population: A Prospective Community-Based Clinical Study. J Am Heart Assoc (2017) 0.75
Inflammation in atherosclerosis. Nature (2002) 28.92
Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med (2005) 28.21
Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum (1995) 26.94
Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthritis Rheum (2003) 8.50
Myocardial infarction redefined--a consensus document of The Joint European Society of Cardiology/American College of Cardiology Committee for the redefinition of myocardial infarction. Eur Heart J (2000) 8.43
Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial. Ann Intern Med (1999) 6.84
Cardiovascular morbidity and mortality in women diagnosed with rheumatoid arthritis. Circulation (2003) 6.62
High incidence of cardiovascular events in a rheumatoid arthritis cohort not explained by traditional cardiac risk factors. Arthritis Rheum (2001) 5.87
Stanford Health Assessment Questionnaire modified to assess disability in British patients with rheumatoid arthritis. Br J Rheumatol (1986) 5.82
Elevated circulating levels of tumor necrosis factor in severe chronic heart failure. N Engl J Med (1990) 5.65
Increased unrecognized coronary heart disease and sudden deaths in rheumatoid arthritis: a population-based cohort study. Arthritis Rheum (2005) 5.31
Cardiovascular death in rheumatoid arthritis: a population-based study. Arthritis Rheum (2005) 4.63
Explaining how "high-grade" systemic inflammation accelerates vascular risk in rheumatoid arthritis. Circulation (2003) 4.52
Update on the British Society for Rheumatology guidelines for prescribing TNFalpha blockers in adults with rheumatoid arthritis (update of previous guidelines of April 2001). Rheumatology (Oxford) (2005) 3.56
Mortality in early inflammatory polyarthritis: cardiovascular mortality is increased in seropositive patients. Arthritis Rheum (2002) 3.53
All-cause mortality and vascular events among patients with rheumatoid arthritis, osteoarthritis, or no arthritis in the UK General Practice Research Database. J Rheumatol (2003) 2.52
Endogenous tumor necrosis factor protects the adult cardiac myocyte against ischemic-induced apoptosis in a murine model of acute myocardial infarction. Proc Natl Acad Sci U S A (2000) 2.25
Plasma cytokine parameters and mortality in patients with chronic heart failure. Circulation (2000) 2.18
Treatment with tumor necrosis factor blockers is associated with a lower incidence of first cardiovascular events in patients with rheumatoid arthritis. J Rheumatol (2005) 2.17
Baseline levels of C-reactive protein and prediction of death from cardiovascular disease in patients with inflammatory polyarthritis: a ten-year followup study of a primary care-based inception cohort. Arthritis Rheum (2005) 2.14
Increase in cardiovascular and cerebrovascular disease prevalence in rheumatoid arthritis. J Rheumatol (2003) 2.07
Longterm mortality outcome in patients with rheumatoid arthritis: early presenters continue to do well. J Rheumatol (1998) 2.00
Stress-activated cytokines and the heart: from adaptation to maladaptation. Annu Rev Physiol (2002) 1.92
How to RECOVER from RENAISSANCE? The significance of the results of RECOVER, RENAISSANCE, RENEWAL and ATTACH. Int J Cardiol (2002) 1.83
The British Society for Rheumatology biologics register. Ann Rheum Dis (2005) 1.66
The transfer of a laboratory based hypothesis to a clinically useful therapy: the development of anti-TNF therapy of rheumatoid arthritis. Best Pract Res Clin Rheumatol (2004) 1.26
Cytokines and hemostasis. Haematologica (2000) 1.17
Inflammation, thrombosis and acute coronary syndromes. Diab Vasc Dis Res (2005) 1.12
Insights into the molecular mechanisms of plaque rupture and thrombosis. Indian Heart J (2005) 0.83
Characterizing the quantitative genetic contribution to rheumatoid arthritis using data from twins. Arthritis Rheum (2000) 6.88
EULAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis. Ann Rheum Dis (2009) 5.82
Outcome of low back pain in general practice: a prospective study. BMJ (1998) 5.27
Features of somatization predict the onset of chronic widespread pain: results of a large population-based study. Arthritis Rheum (2001) 4.85
Rates of serious infection, including site-specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy: results from the British Society for Rheumatology Biologics Register. Arthritis Rheum (2006) 4.20
Outcomes after switching from one anti-tumor necrosis factor alpha agent to a second anti-tumor necrosis factor alpha agent in patients with rheumatoid arthritis: results from a large UK national cohort study. Arthritis Rheum (2007) 3.99
The prevalence of rheumatoid arthritis in the United Kingdom: new estimates for a new century. Rheumatology (Oxford) (2002) 3.87
The incidence of rheumatoid arthritis in the United Kingdom: results from the Norfolk Arthritis Register. Br J Rheumatol (1994) 3.82
Predictors of response to anti-TNF-alpha therapy among patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register. Rheumatology (Oxford) (2006) 3.73
The prevalence of vertebral deformity in european men and women: the European Vertebral Osteoporosis Study. J Bone Miner Res (1996) 3.25
Estimating the prevalence of low back pain in the general population. Evidence from the South Manchester Back Pain Survey. Spine (Phila Pa 1976) (1995) 3.18
Incidence of vertebral fracture in europe: results from the European Prospective Osteoporosis Study (EPOS). J Bone Miner Res (2002) 3.16
Anti-TNF therapy is associated with an increased risk of serious infections in patients with rheumatoid arthritis especially in the first 6 months of treatment: updated results from the British Society for Rheumatology Biologics Register with special emphasis on risks in the elderly. Rheumatology (Oxford) (2010) 3.04
Influence of disease-modifying therapy on radiographic outcome in inflammatory polyarthritis at five years: results from a large observational inception study. Arthritis Rheum (2003) 2.97
Blood transfusion, smoking, and obesity as risk factors for the development of rheumatoid arthritis: results from a primary care-based incident case-control study in Norfolk, England. Arthritis Rheum (1997) 2.90
A comparison of the performance of different methods of disease classification for rheumatoid arthritis. Results of an analysis from a nationwide twin study. J Rheumatol (1994) 2.87
Widespread body pain and mortality: prospective population based study. BMJ (2001) 2.85
A disease severity scale for systemic sclerosis: development and testing. J Rheumatol (1999) 2.85
Sjögren's syndrome: a community-based study of prevalence and impact. Br J Rheumatol (1998) 2.67
The role of psychosocial factors in predicting the onset of chronic widespread pain: results from a prospective population-based study. Rheumatology (Oxford) (2006) 2.66
Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology Biologics Register (BSRBR). Ann Rheum Dis (2009) 2.65
Predicting who develops chronic low back pain in primary care: a prospective study. BMJ (1999) 2.62
Skin thickness score in systemic sclerosis: an assessment of interobserver variability in 3 independent studies. J Rheumatol (1993) 2.56
Role of mechanical and psychosocial factors in the onset of forearm pain: prospective population based study. BMJ (2000) 2.56
Validity of self-report of fractures: results from a prospective study in men and women across Europe. EPOS Study Group. European Prospective Osteoporosis Study Group. Osteoporos Int (2000) 2.52
Age-sex registers as a screening tool for general practice: size of the wrong address problem. Br Med J (Clin Res Ed) (1984) 2.51
Estimating the prevalence of delayed median nerve conduction in the general population. Br J Rheumatol (1998) 2.50
European multicentre study to define disease activity criteria for systemic sclerosis. II. Identification of disease activity variables and development of preliminary activity indexes. Ann Rheum Dis (2001) 2.49
Serious infection following anti-tumor necrosis factor alpha therapy in patients with rheumatoid arthritis: lessons from interpreting data from observational studies. Arthritis Rheum (2007) 2.46
Occupational risk factors for shoulder pain: a systematic review. Occup Environ Med (2000) 2.40
Development and validation of a questionnaire to assess disabling foot pain. Pain (2000) 2.34
Prevalence of shoulder pain in the community: the influence of case definition. Ann Rheum Dis (1997) 2.28
The prevalence and associated features of chronic widespread pain in the community using the 'Manchester' definition of chronic widespread pain. Rheumatology (Oxford) (1999) 2.21
Influence of previous pain experience on the episode incidence of low back pain: results from the South Manchester Back Pain Study. Pain (1996) 2.17
Classification criteria for rheumatoid arthritis--time to abandon rheumatoid factor? Rheumatology (Oxford) (2007) 2.15
A family history of fracture and fracture risk: a meta-analysis. Bone (2004) 2.13
Cardiovascular admissions and mortality in an inception cohort of patients with rheumatoid arthritis with onset in the 1980s and 1990s. Ann Rheum Dis (2005) 2.11
Musculoskeletal pain is associated with a long-term increased risk of cancer and cardiovascular-related mortality. Rheumatology (Oxford) (2009) 2.09
Differences in the characteristics of responders and non-responders in a prevalence survey of vertebral osteoporosis. European Vertebral Osteoporosis Study Group. Osteoporos Int (1995) 2.09
Risk factors for neck pain: a longitudinal study in the general population. Pain (2001) 2.06
Psychosocial factors in the workplace--do they predict new episodes of low back pain? Evidence from the South Manchester Back Pain Study. Spine (Phila Pa 1976) (1997) 2.01
Association of rheumatoid factor and anti-cyclic citrullinated peptide positivity, but not carriage of shared epitope or PTPN22 susceptibility variants, with anti-tumour necrosis factor response in rheumatoid arthritis. Ann Rheum Dis (2008) 2.01
Is musculoskeletal pain more common now than 40 years ago?: Two population-based cross-sectional studies. Rheumatology (Oxford) (2005) 1.99
Impact of concomitant use of DMARDs on the persistence with anti-TNF therapies in patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register. Ann Rheum Dis (2011) 1.99
Psychologic distress and low back pain. Evidence from a prospective study in the general population. Spine (Phila Pa 1976) (1995) 1.98
Relation of risk of systemic lupus erythematosus to west African admixture in a Caribbean population. Hum Genet (2003) 1.97
Radiographic osteoarthritis of the knee classified by the Ahlbäck and Kellgren & Lawrence systems for the tibiofemoral joint in people aged 35-54 years with chronic knee pain. Ann Rheum Dis (1997) 1.95
Does rheumatoid arthritis remit during pregnancy and relapse postpartum? Results from a nationwide study in the United Kingdom performed prospectively from late pregnancy. Arthritis Rheum (1999) 1.94
Effects of switching between anti-TNF therapies on HAQ response in patients who do not respond to their first anti-TNF drug. Rheumatology (Oxford) (2008) 1.91
Chronic widespread pain in the community: the influence of psychological symptoms and mental disorder on healthcare seeking behavior. J Rheumatol (1999) 1.90
Regional differences in survival from cancer. Community Med (1981) 1.85
Widespread pain: is an improved classification possible? J Rheumatol (1996) 1.83
The influence of anti-TNF therapy upon incidence of keratinocyte skin cancer in patients with rheumatoid arthritis: longitudinal results from the British Society for Rheumatology Biologics Register. Ann Rheum Dis (2012) 1.80
Interferon-alpha does not improve outcome at one year in patients with diffuse cutaneous scleroderma: results of a randomized, double-blind, placebo-controlled trial. Arthritis Rheum (1999) 1.79
Incidence of distal forearm fracture in British men and women. Osteoporos Int (2001) 1.79
Clinical signs of early osteoarthritis: reproducibility and relation to x ray changes in 541 women in the general population. Ann Rheum Dis (1991) 1.79
Estimating the incidence of rheumatoid arthritis: trying to hit a moving target? Arthritis Rheum (1999) 1.78
Mortality associated with vertebral deformity in men and women: results from the European Prospective Osteoporosis Study (EPOS). Osteoporos Int (1998) 1.76
No evidence of association between anti-tumor necrosis factor treatment and mortality in patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register. Arthritis Rheum (2010) 1.73
The influence of work related psychosocial factors and psychological distress on regional musculoskeletal pain: a study of newly employed workers. J Rheumatol (2001) 1.72
Time to first occurrence of erosions in inflammatory polyarthritis: results from a prospective community-based study. Arthritis Rheum (2001) 1.71
The association of cigarette smoking with disease outcome in patients with early inflammatory polyarthritis. Arthritis Rheum (2001) 1.71
The grading of hallux valgus. The Manchester Scale. J Am Podiatr Med Assoc (2001) 1.70
Health-related quality of life and radiographic vertebral fracture. Osteoporos Int (2003) 1.70
Natural remission in inflammatory polyarthritis: issues of definition and prediction. Br J Rheumatol (1996) 1.67
Behçet's disease: evaluation of a new instrument to measure clinical activity. Rheumatology (Oxford) (1999) 1.66
The performance of the 1987 ARA classification criteria for rheumatoid arthritis in a population based cohort of patients with early inflammatory polyarthritis. American Rheumatism Association. J Rheumatol (1998) 1.63
Beneficial effects of a 3-week course of intramuscular glucocorticoid injections in patients with very early inflammatory polyarthritis: results of the STIVEA trial. Ann Rheum Dis (2009) 1.63
The pill, parity, and rheumatoid arthritis. Arthritis Rheum (1990) 1.62
Low back pain in schoolchildren: the role of mechanical and psychosocial factors. Arch Dis Child (2003) 1.61